Navigation Links
NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
Date:4/28/2011

ass="discStyle" type="disc">
  • Patents relating to capsaicin prodrugs entitled, "TRPV1 Agonist Compounds and Methods for Making and Using the Same," have issued in the United Stated and Mexico.

    • Patents relating to capsaicin oils entitled, "Oils of Capsaicinoids and Methods of Making and Using the Same," have issued in the United States, throughout Europe and Eurasia.

    • With respect to the skin cleansing gel, which is a component of the Qutenza treatment kit and is used to remove residual capsaicin from the skin after a Qutenza treatment, patents entitled, "Compositions and Kits for the Removal of Irritating Compounds from Bodily Surfaces," have issued in Eurasia and Japan.  

    • A patent relating to a capsaicin patch including specific penetration enhancers entitled, "Device for Delivery of TRPV1 Agonists," has issued in South Africa.

    About NeurogesX, Inc.

    NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

    The Company's lead product, Qutenza®, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza&#
    '/>"/>

    SOURCE NeurogesX
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
    2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
    3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
    4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
    5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
    6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
    7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
    8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
    9. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
    10. NeurogesX to Present at JMP Securities Healthcare Focus Conference
    11. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, Inc. ... announced it has completed the sale to Galderma of ... owned or held by Valeant for $1.4 billion in ... S.A, which recently completed its acquisition of Galderma. ... of our products to a company that is firmly ...
    (Date:7/10/2014)... CVS Caremark Corporation (NYSE: CVS ) ... quarterly dividend of $0.275 (27.5 cents) per share on the ... 2014, to holders of record on July 21, 2014. ... dedicated to helping people on their path to better health ... United States . Through the company,s more than 7,600 ...
    (Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
    Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
    (Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Polio is history ... places like Afghanistan, Nigeria and Pakistan. Giving vaccinated children ... their immunity and help eradicate the highly infectious disease, ... is highly effective, immunity wanes as early as a ... be infected and contribute to the spread of the ...
    (Date:7/11/2014)... breast cancer patients, the era of personalized medicine may ... by USC Stem Cell researcher Min Yu and scientists ... In a July 11 study in Science , ... cancer cells circulating through the blood streams of six ... "seeds" of metastasis, which travel to and establish secondary ...
    (Date:7/11/2014)... FL (PRWEB) July 11, 2014 American ... on RFD-TV, next Tuesday, July 15, 2014, at 8:30 ... Sunbelt's line of proprietary products, which are designed and ... crops. Audiences will learn how these products help the ... environment in which it is grown. , The show ...
    (Date:7/11/2014)... Shoulder instability is a common injury in ... has not been regularly determined following surgery. A new ... Medicine’s ( AOSSM ) Annual Meeting today details that ... no matter what the stabilization procedure (open vs. arthroscopic). ... to play following shoulder stabilization surgery. Age, number of ...
    (Date:7/11/2014)... Anterior Cruciate Ligament (ACL) reconstructions occur more ... material used to create a new ligament may determine ... presenting their work today at the Annual Meeting of ... ). , “Our study results highlight that ... a donor) fail more frequently than using autografts (tissue ...
    Breaking Medicine News(10 mins):Health News:Researchers Assess New Way to Boost Polio Immunity 2Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2Health News:Stabilizing Shoulder Surgery Helps NFL Players Return to the Game 2Health News:ACL Reconstructions May Last Longer With Autografts 2
    ... , SINGAPORE, Nov. 16 /PRNewswire-Asia/ ... Malaysia grew steadily in the first half of 2009 with,total ... promotions from major Contact Lens manufacturers. Positive sales,data showing a ... view of an economic recovery that is being led by ...
    ... ... Critical Strategies for Successful Interactions Between Life Science Companies and Health Care Providers ... ... sales enablement and IT consulting company, today announced that UCB, a global biopharmaceutical ...
    ... ... Kids who Wear Ankle-Foot Orthoses (AFOs) , ... Westchester, NY (PRWEB) November 16, 2009 -- Ross Daniel Adaptive Apparel ... and the launch of “Cool Clothes for Toes,” the first creatively styled sock line for ...
    ... NANJING, China, Nov. 16 /PRNewswire-Asia/ -- Simcere Pharmaceutical ... pharmaceutical company,specializing in the development, manufacturing, and marketing of branded,generic and ... ended September 30, 2009. , , Highlights, ... the third, quarter of 2009, ...
    ... , Study highlights: , In patients with or ... treated with statins to < 100mg/dL but low HDL (good ... LDL further. , Patients were randomized to the addition of ... LDL cholesterol). Plaque buildup in the lining of the ...
    ... ... to begin the drug registration process in Brazil and Colombia for its over-the-counter pain ... for the treatment of moderate to severe (Stage 2) chronic pain. , ... Plantation, FL (Vocus) November 15, ...
    Cached Medicine News:Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 3Health News:Leading Biopharmaceutical Company Selects Stimar for Code of Conduct Regulation Training 2Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 2Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 3Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 12Health News:American Heart Association Late Breaking Clinical Trial Report: In Patients on Statins, Raising Good Cholesterol with Niacin, but not Reducing Bad Cholesterol with Ezetimibe, Decreases Plaque Build-Up 2Health News:American Heart Association Late Breaking Clinical Trial Report: In Patients on Statins, Raising Good Cholesterol with Niacin, but not Reducing Bad Cholesterol with Ezetimibe, Decreases Plaque Build-Up 3Health News:American Heart Association Late Breaking Clinical Trial Report: In Patients on Statins, Raising Good Cholesterol with Niacin, but not Reducing Bad Cholesterol with Ezetimibe, Decreases Plaque Build-Up 4Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 2Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 3Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 4
    ... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
    ... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
    ... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
    ... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
    Medicine Products: